<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620163</url>
  </required_header>
  <id_info>
    <org_study_id>YH22162-301</org_study_id>
    <nct_id>NCT02620163</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in
      patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8</measure>
    <time_frame>baseline and week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 2</measure>
    <time_frame>baseline and week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4</measure>
    <time_frame>baseline and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 2</measure>
    <time_frame>baseline and week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 4</measure>
    <time_frame>baseline and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 8</measure>
    <time_frame>baseline and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Blood Pressure Control at Week 2</measure>
    <time_frame>baseline and week 2</time_frame>
    <description>Mean sitting blood pressure(MSBP) &lt; 140/90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Blood Pressure Control at Week 4</measure>
    <time_frame>baseline and week 4</time_frame>
    <description>Mean sitting blood pressure(MSBP) &lt; 140/90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Blood Pressure Control at Week 8</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>Mean sitting blood pressure(MSBP) &lt; 140/90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 2</measure>
    <time_frame>baseline and week 2</time_frame>
    <description>reduction of MSSBP&gt;= 20 mmHg and reduction of MSSBP&gt;= 10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 4</measure>
    <time_frame>baseline and week 4</time_frame>
    <description>reduction of MSSBP&gt;= 20 mmHg and reduction of MSSBP&gt;= 10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 8</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>reduction of MSSBP&gt;= 20 mmHg and reduction of MSSBP&gt;= 10 mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">381</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>YH22162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>telmisartan/amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan/amlodipine 40/5mg</intervention_name>
    <arm_group_label>telmisartan/amlodipine</arm_group_label>
    <other_name>Twynsta 40/5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH22162 40/5/12.5 mg</intervention_name>
    <arm_group_label>YH22162</arm_group_label>
    <other_name>telmisartan/amlodipine/chlorthalidone 40/5/12.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan/amlodipine 80/5mg</intervention_name>
    <arm_group_label>telmisartan/amlodipine</arm_group_label>
    <other_name>Twynsta 80/5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH22162 80/5/25 mg</intervention_name>
    <arm_group_label>YH22162</arm_group_label>
    <other_name>telmisartan/amlodipine/chlorthalidone 80/5/25 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan/amlodipine 40/5mg placebo</intervention_name>
    <arm_group_label>YH22162</arm_group_label>
    <other_name>Twynsta 40/5 mg placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH22162 40/5/12.5 mg placebo</intervention_name>
    <arm_group_label>telmisartan/amlodipine</arm_group_label>
    <other_name>telmisartan/amlodipine/chlorthalidone 40/5/12.5 mg placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan/amlodipine 80/5mg placebo</intervention_name>
    <arm_group_label>YH22162</arm_group_label>
    <other_name>Twynsta 80/5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH22162 80/5/25 mg placebo</intervention_name>
    <arm_group_label>telmisartan/amlodipine</arm_group_label>
    <other_name>telmisartan/amlodipine/chlorthalidone 80/5/25 mg placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent

          -  Men and women ≥ 19 years of age

          -  Essential hypertensive patients

               1. If already taking antihypertensive drugs, mean sitting systolic blood pressure
                  (MSSBP) must be 140 mmHg ≤ MSSBP &lt; 200 mmHg

               2. If not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic
                  blood pressure (MSSBP) must be 160 mmHg ≤ MSSBP &lt; 200 mmHg

        Exclusion Criteria:

          -  Patients with known or suspected secondary hypertension

          -  Other exclusions applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyunhee Na, MD</last_name>
    <role>Study Director</role>
    <affiliation>Yuhan Corporation</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2015</study_first_submitted>
  <study_first_submitted_qc>November 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

